Olimelen 9 Injection

Adult administration

Recommended daily dosage - 0.16 g-0.35 g per kg of body weight as nitrogen (1 g-2 g per kg of body weight as amino acids) - 20-40 kcal per kg of body weight as total calories - 20-40 mL per kg of body weight as total administered volume or 1-1.5 mL per calorie consumed Maximum daily dosage - 35 mL per kg of body weight (2.0 g of amino acids, 3.9 g of glucose, 1.4 g of lipids)

Child administration

1. Children aged 2 to 11 years Maximum daily dosage - 25 mL per kg of body weight (1.4 g of amino acids, 2.8 g of glucose, 1.0 g of lipids, total calories 26.8 kcal per kg)

This medication must be used according to the physician's instructions, and it should not be used arbitrarily based on personal judgment. If signs of anaphylactic reactions such as fever, chills, rash, or difficulty breathing occur during administration of this medication, stop administration immediately and consult a medical professional. When mixed with intravenous calcium-containing preparations and Ceftriaxone, there is a risk of the formation of Ceftriaxone-calcium precipitate, so this medication and calcium-containing preparations should not be administered with the same infusion device simultaneously. Premature infants and low birth weight infants have low lipid metabolism capability, so caution is especially needed when administering the lipid components of this medication as they may accumulate in the body. This medication should not be administered to certain patients such as premature infants, newborns, children under 2 years old, patients with specific allergies, severe renal impairment, or liver disease, as its use is prohibited in these populations. Patients with renal failure, diabetes, liver dysfunction, heart failure, and other diseases affecting lipid metabolism must use this medication more cautiously, and it is important to improve their condition prior to administration. Excessive administration or too rapid infusion rates of this medication can cause side effects, hence proper dosage and rates must be adhered to. During the initial administration period, abnormal symptoms such as sweating, fever, chills, headache, rash, and difficulty breathing may occur, so if these symptoms arise, administration should be stopped immediately. While undergoing treatment, it is essential to regularly monitor fluid and electrolyte balance, blood glucose, liver and kidney function, and blood lipid levels, and prompt action must be taken if any abnormalities are detected. This medication must be administered via a central vein and if there is extravasation during infusion, it must be stopped immediately, and appropriate measures should be taken. The safety for pregnant and breastfeeding women has not been established, so this medication should only be administered when the therapeutic benefits outweigh the risks. In pediatric patients, it may only be administered to those aged 2 years and older, and pediatric vitamins and trace elements must be supplemented during administration. This medication poses a risk of precipitate formation when mixed or co-administered with other drugs, and must be mixed and administered following the expert's directions. In cases of overdose, symptoms may include acidosis, fluid overload, and hyperglycemia, and in severe cases, treatments such as blood dialysis may be needed. During the use of this medication, it is crucial to ensure catheter management and aseptic techniques to prevent infection, and if signs of infection arise, it should be reported to a medical professional immediately. After administration of this medication, it may affect certain clinical test results, so it is advisable to consult with medical professionals about the timing and method of tests.

Serious side effects

• Rash
• difficulty breathing
• thrombocytopenia
• cholestasis
• liver enlargement
• jaundice
• pulmonary vascular embolism
• difficulty breathing
• lipid overload syndrome
• coma

Mild side effects

• Sweating
• fever
• chills
• headache
• rash
• itching
• flushing
• tachycardia
• loss of appetite
• hypertriglyceridemia

This medication should be stored in a sealed container to prevent air ingress. The storage temperature should be maintained at room temperature, ensuring that the medication does not freeze.

Appearance

A transparent plastic bag divided into three compartments by two membranes, where the amino acid solution and sugar solution are clear, colorless to pale yellow liquids, and the fat solution is a homogeneous milky liquid.

Package unit

1000ml (400ml amino acid solution, 400ml sugar solution, 200ml fat solution), 1500ml (600ml amino acid solution, 600ml sugar solution, 300ml fat solution), 2000ml (800ml amino acid solution, 800ml sugar solution, 400ml fat solution)